Encrypgen allows individual donors to control and even sell access to their private genetic information with private encryption keys
Encrypgen, a leading innovator in the Blockchain genomic storage and security industry, have raised over 1 Million USD through their ongoing Token Sale. The company, led by the renowned scientist and author Dr. David Koepsell, has already reached more than half of their intended sale goal at 55%.
This low-key token sale (or ‘ICO’) for a high-profile product has seen significant growth due to word-of-mouth marketing by its core enthusiasts. Encrypgen makes genomic data storage private and robust through Blockchain and encryption technology. The Encrypgen team highlighted that they are on the verge of closing a number of sales for their beta application to research institutes. The beta has successfully assimilated a vast library of public genetic data.
Encrypgen allows individual donors to control and even sell access to their private genetic information with private encryption keys. Encrypgen is not ready to confirm (or deny) the rumor that a “whale” ICO investment fund plans to buy out all remaining tokens before the end of the token sale. The Gene-Chain coin token bonuses of 300K and 500K are still available to buyers of over 75BTC and 100BTC respectively. Meanwhile the largest buyer so far with 52BTC stands to earn a 1M Gene-Chain coin bonus.
Encrypgen is very busy with continued marketing and development to build application sales and revenue, and less focused on promoting their token sale. With a prescient focus on disrupting genomic data management, Dr David Koepsell says: “We continue to seek a brave and forward-thinking client who is interested and willing to help make their genomic data storage and sharing more secure, and facilitate what we are trying to create as a new marketplace for that data.”
